Pacira BioSciences reported second quarter 2026 total revenues of $192.4 million, a 6% increase over the prior year, and updated full-year guidance to $735 million to $760 million following the divestiture of iovera to Zimmer Biomet. EXPAREL net sales rose 3% to $147.8 million, ZILRETTA sales grew 4% to $32.6 million, and iovera sales increased 21% to $6.8 million. The company highlighted UnitedHealthcare's decision to provide separate reimbursement for EXPAREL outside the surgical bundle, bringing total covered lives to over 150 million, and noted that ZILRETTA was placed on UnitedHealthcare's preferred drug list. Pacira expects top-line data from three registrational studies later this year: the iovera spasticity study, the ZILRETTA shoulder osteoarthritis study, and Part A of the Phase 2 PCRX-201 study.
Pacira BioSciences, Inc.Q2 revenues up 6%, guidance updated, and reimbursement wins for EXPAREL and ZILRETTA.
UnitedHealth Group IncorporatedUnitedHealthcare's reimbursement decisions for EXPAREL and ZILRETTA are positive for its business.
Zimmer Biomet Holdings Inc